This study is an open-label, phase 1, inter-patient dose escalation feasibility trial seeking
establish preliminary tolerability, efficacy, and pharmacokinetic data for up to 4 different
doses of inhaled tobramycin administered to very preterm infants with BPD who are receiving
invasive mechanical ventilation and have a pathogenic Gram-negative organism detected by
tracheal aspirate culture.